PT3007721T - Bioconjugados não-aglomerantes de compostos miméticos de amilina e polietilenoglicol - Google Patents
Bioconjugados não-aglomerantes de compostos miméticos de amilina e polietilenoglicolInfo
- Publication number
- PT3007721T PT3007721T PT14810520T PT14810520T PT3007721T PT 3007721 T PT3007721 T PT 3007721T PT 14810520 T PT14810520 T PT 14810520T PT 14810520 T PT14810520 T PT 14810520T PT 3007721 T PT3007721 T PT 3007721T
- Authority
- PT
- Portugal
- Prior art keywords
- amylin
- polyethyleneglycol
- mimetic compounds
- agglomerating bioconjugates
- bioconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRBR102013017626-5A BR102013017626A2 (pt) | 2013-06-14 | 2013-06-14 | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3007721T true PT3007721T (pt) | 2019-05-13 |
Family
ID=52021510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT14810520T PT3007721T (pt) | 2013-06-14 | 2014-06-13 | Bioconjugados não-aglomerantes de compostos miméticos de amilina e polietilenoglicol |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160331811A1 (pt) |
EP (1) | EP3007721B1 (pt) |
JP (1) | JP2016526533A (pt) |
CN (1) | CN105658234A (pt) |
AU (1) | AU2014280869B2 (pt) |
BR (1) | BR102013017626A2 (pt) |
CA (1) | CA2915104A1 (pt) |
ES (1) | ES2720274T3 (pt) |
MX (1) | MX368485B (pt) |
PL (1) | PL3007721T3 (pt) |
PT (1) | PT3007721T (pt) |
TR (1) | TR201906773T4 (pt) |
WO (1) | WO2014197961A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
ES2922252T3 (es) * | 2016-08-12 | 2022-09-12 | Ericsson Telefon Ab L M | Selección de una portadora en un sistema de operación multiportadora |
TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
CA2475173A1 (en) * | 2002-01-08 | 2003-07-17 | Amylin Pharmaceuticals, Inc. | Use of amylin agonists to modulate triglycerides |
US20040209801A1 (en) * | 2002-10-22 | 2004-10-21 | Brand Stephen J. | Treatment of diabetes |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US8114958B2 (en) * | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
DE602006008456D1 (de) * | 2005-03-31 | 2009-09-24 | Amylin Pharmaceuticals Inc | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen |
PL1877099T3 (pl) * | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
EP1874339A1 (en) * | 2005-04-21 | 2008-01-09 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
CN101400698A (zh) * | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
EP2102355B1 (en) * | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
US20110135623A1 (en) * | 2008-05-16 | 2011-06-09 | Nektar Therapeutics | Conjugates of a Cholinesterase Moiety and a Polymer |
ES2579502T3 (es) * | 2008-06-17 | 2016-08-11 | Indiana University Research And Technology Corporation | Coagonistas de receptores de glucagón/GLP-1 |
MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
BRPI1003424A2 (pt) * | 2010-09-08 | 2013-01-08 | Univ Rio De Janeiro | sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada |
IL295201A (en) * | 2010-11-12 | 2022-10-01 | Nektar Therapeutics | Conjugations of a part of il-2 and a polymer, preparations containing them and their uses |
US20140221282A1 (en) * | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
US20140256621A1 (en) * | 2011-07-08 | 2014-09-11 | Astrazeneca Pharmaceuticals Lp | Engineered poypeptides having enhanced duration of action and reduced immunogenicity |
WO2013059336A1 (en) * | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
WO2014152820A1 (en) * | 2013-03-14 | 2014-09-25 | Vdopia Inc. | Systems and methods for layering content |
-
2013
- 2013-06-14 BR BRBR102013017626-5A patent/BR102013017626A2/pt not_active Application Discontinuation
-
2014
- 2014-06-13 WO PCT/BR2014/000199 patent/WO2014197961A1/en active Application Filing
- 2014-06-13 TR TR2019/06773T patent/TR201906773T4/tr unknown
- 2014-06-13 JP JP2016518806A patent/JP2016526533A/ja active Pending
- 2014-06-13 MX MX2015017356A patent/MX368485B/es active IP Right Grant
- 2014-06-13 AU AU2014280869A patent/AU2014280869B2/en not_active Ceased
- 2014-06-13 PL PL14810520T patent/PL3007721T3/pl unknown
- 2014-06-13 US US14/898,237 patent/US20160331811A1/en not_active Abandoned
- 2014-06-13 PT PT14810520T patent/PT3007721T/pt unknown
- 2014-06-13 CN CN201480033501.8A patent/CN105658234A/zh active Pending
- 2014-06-13 EP EP14810520.8A patent/EP3007721B1/en not_active Not-in-force
- 2014-06-13 ES ES14810520T patent/ES2720274T3/es active Active
- 2014-06-13 CA CA2915104A patent/CA2915104A1/en not_active Abandoned
-
2015
- 2015-12-14 US US14/968,033 patent/US20160184401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2015017356A (es) | 2016-12-20 |
CA2915104A1 (en) | 2014-12-18 |
PL3007721T3 (pl) | 2019-09-30 |
CN105658234A (zh) | 2016-06-08 |
EP3007721B1 (en) | 2019-02-27 |
ES2720274T3 (es) | 2019-07-19 |
EP3007721A1 (en) | 2016-04-20 |
TR201906773T4 (tr) | 2019-05-21 |
EP3007721A4 (en) | 2016-12-07 |
WO2014197961A9 (en) | 2016-01-28 |
AU2014280869A1 (en) | 2016-01-07 |
US20160331811A1 (en) | 2016-11-17 |
AU2014280869B2 (en) | 2017-11-02 |
JP2016526533A (ja) | 2016-09-05 |
BR102013017626A2 (pt) | 2015-02-10 |
US20160184401A1 (en) | 2016-06-30 |
WO2014197961A1 (en) | 2014-12-18 |
MX368485B (es) | 2019-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180635T1 (hr) | Pirazolamidni spoj i njegova upotreba u medicini | |
HK1208337A1 (en) | Face protector | |
HK1254296A1 (zh) | 治療性化合物和其用途 | |
EP2949050A4 (en) | DISPLAY OF AN NFC POSITION | |
HK1221416A1 (zh) | 氧雜雙環庚烷和氧雜雙環庚烯的配製品 | |
HRP20181710T1 (hr) | Uporaba derivata benzimidazol-prolina | |
HK1217092A1 (zh) | 治療性化合物及其用途 | |
IL244214B (en) | Thienopiperidine derivative and its use | |
SG11201507389RA (en) | Integration of hydro-dechlorination and hydro-regeneration | |
SG10201403043XA (en) | Medical face masks | |
GB201313900D0 (en) | Tumour-targeted theranostic | |
GB201311107D0 (en) | Bioorthogonal methods and compounds | |
EP3007721A4 (en) | BIOCONJUGATES OF MIMETIC COMPOUNDS OF AMYLINE AND POLYETHYLENE GLYCOL DO NOT AGGLOMERATE | |
HK1219662A1 (zh) | 血脂異常症治療劑 | |
EP2968557A4 (en) | IMPROVING VACCINES | |
GB201304608D0 (en) | BenTime of Yisrael operable arrangement | |
GB201304166D0 (en) | CelebQuiff and Instant Quiff | |
GB201307202D0 (en) | New compounds and uses | |
GB201307201D0 (en) | New compounds and uses | |
GB201310540D0 (en) | Mattress protector | |
GB201301734D0 (en) | New compounds and uses | |
GB201301393D0 (en) | Kiddibidet and pottibidet |